Medical Center-Sv. Dimitar EOOD
- Address
- 8, Kumata Str., 1616 Sofia, Bulgaria
Nutritional and Metabolic Diseases Research
The clinical trial activity at Medical Center-Sv. Dimitar EOOD in Sofia focuses on Nutritional and Metabolic Diseases, with studies centered on hypertriglyceridemia and obesity. This research is aimed at evaluating new treatment options, measuring their ability to improve metabolic health, and assessing longer-term safety in people living with these conditions.
- Hypertriglyceridemia treatment research
- Obesity management studies
- Testing new therapies to improve metabolic outcomes
Current trials include efforts to lower fasting serum triglyceride levels, examine safety over time in patients with elevated triglycerides, and compare a newer obesity treatment with established options to see whether it offers better weight reduction.
Metabolic Health and Lipid Disorder Studies
Research at this site also highlights the management of lipid disorders, especially hypertriglyceridemia and its more severe forms. The trials are designed to help determine whether investigational therapies can better control triglyceride levels and provide durable benefit for people with ongoing metabolic risk.
- Hypertriglyceridemia (HTG) control
- Long-term safety evaluation of new treatments
- Improving care for patients with elevated triglycerides
These studies are part of a broader effort to improve treatment effectiveness in cardiometabolic care, while also supporting safer and more targeted approaches for patients who need better disease control.
Obesity Treatment Research
The site is contributing to clinical research in obesity, with trials focused on comparing therapies that may help reduce body weight in adults without diabetes. The goal is to evaluate whether new options can offer stronger weight-loss effects and support better long-term management of excess weight.
- Obesity outcomes research
- Comparing treatment effectiveness for weight reduction
- Evaluating potential new anti-obesity therapies
By studying both effectiveness and safety, the research at Medical Center-Sv. Dimitar EOOD supports the development of better approaches for patients affected by chronic metabolic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Arrowhead Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Arrowhead Pharmaceuticals Inc.3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center-Sv. Dimitar EOOD
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Study to Compare the Efficacy and Safety of KAI-9531 Versus Semaglutide in Participants Living with Obesity Without Diabetes | Kailera Therapeutics Inc. | Phase III | Recruiting | Jun 2026 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues | 3 | Unknown | 2024-11-04 | 2025-12-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.